Abstract: Provided herein are transdermal delivery devices comprising tetrabenazine, a deuterated tetrabenazine, or a combination thereof. Also provided herein are pharmaceutical compositions, such as adhesive compositions, comprising tetrabenazine, a deuterated tetrabenazine, or a combination thereof, for example, homogenously dispersed in an adhesive, such as a pressure sensitive adhesive. Further provided herein are methods of using the transdermal delivery devices or pharmaceutical compositions, for example, for treating a hyperkinetic movement disorder.

Abstract: The present invention refers to compounds of the carotenoid class, such as lycopene or lacto-lycopene, for their use in the treatment and/or prevention of toxicity caused by antitumor drugs, as well as their use in the treatment or remission of tumors in combination with antitumor drugs. Finally, the present invention refers to the combination of the above set forth compounds and drugs with antitumor action.

Abstract: The present invention provides a novel composition for preventing and/or improving brain dysfunction comprising a lutein or a salt thereof and a plant product of the genus Trapa as active ingredients, particularly a composition for use as a pharmaceutical product and a food and beverage.

Abstract: A pet food supplement is provided. The pet food supplement includes the following therapeutic components: curcumin bioavailability, joint preserving and building, fat soluble vitamin absorption, immune system preserving and building, and cancer prevention. One embodiment of the pet food supplement includes turmeric, BIOPERINE®, glucosamine, Chondroitin Sulfate, Methylsulfonylmethane, Sodium Hyaluronate, Vitamin B1, Vitamin C, Vitamin E, Manganese, Zinc, kelp, grape seed extract, Vitamin B6, Vitamin B9, Vitamin B12, the Vitamin C, Vitamin A, Vitamin D, Vitamin K, Omega-3, and Omega-6. Each of these ingredients is premixed and orally delivered to the pet in the form of a powder, paste or segment having a size and weight or other dosage measuring feature adjusted in accordance with a weight of the pet.

Abstract: Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.

Abstract: The present invention relates to methods tor the treatment or prevention of fatigue associated with disordered sleep, for example, in multiple sclerosis, fibromyalgia, Fabry's disease, Parkinson's disease, or traumatic brain injury, using cyclobenzaprine. The present invention further relates to a biomarker for the therapeutic effects of a cyclobenzaprine treatment.

Abstract: The present invention relates to a pharmaceutical combination of ambroxol or a pharmaceutically acceptable salt thereof and dropropizine. Moreover, it refers to a pharmaceutical composition, preferably in a form of oral administration, containing said active ingredients, together with one or more pharmaceutically acceptable additives. The invention also relates to the preparation processes and the processes of use of the pharmaceutical combination or the pharmaceutical composition of the present invention.

Abstract: A method of forming an implant in tissue can include: providing a polymer solution having an effective amount of polymer dissolved in a biocompatible, water-soluble organic solvent; injecting a plurality of droplets of the polymer solution in the tissue; fusing the injected droplets together; dissipating the biocompatible, water-soluble organic solvent in the tissue; and precipitating the polymer from the injected polymer solution so as to form the implant.

Abstract: Embodiments of a method and/or system can include administering, to a patient with one or more conditions associated with at least one of TMA, TMAO, and/or derivatives thereof, a therapeutically effective amount of a compound for affecting inhibiting one or more CutC enzymes and/or CntA enzymes associated with microorganisms from at least one taxon from a set of microorganism taxa.

Abstract: Disclosed herein are methods for improving digestive health by providing a consumable composition. Some embodiments provided include, for example, administering a compound of Formula (I) or compound of Formula (II). Some embodiments provide the composition is formulated as a dietary supplement, food ingredient or additive, a medical food, nutraceutical or pharmaceutical composition.

Abstract: Methods to interrogate and modulate gut barrier integrity are provided. Methods for treating leaky gut barrier are also provided. Methods for early detection of diseases associated with inflammatory disorders. Methods to rapidly assess the effects of drugs, chemicals, nutritional supplements, vitamins, and probiotics on the integrity of the gut barrier are also provided.

Abstract: The present invention relates to certain compounds of formula (I) wherein—Ar is (Ar1) or (Ar2) and to their uses as antibacterial agents. The invention further relates to methods of treatment of bacterial infection with such compounds, optionally in combination with other antimicrobials and to compositions and pharmaceutical formulations containing such compounds. The invention additionally relates to coatings containing such compounds and to items having such coatings.

Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.

Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.

Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Abstract: The present invention belongs to the technical field of medicine, and specifically relates to use of succinic acid in increasing sensitivity of bacteria to antibiotics. The present invention found that the succinic acid can increase proton motive force of bacteria, thereby increasing the number of antibiotics entering the bacteria, and eventually killing the bacteria. Therefore, the succinic acid can increase the sensitivity of bacteria to antibiotics, thereby overcoming the problem of bacterial drug resistance. Combining succinic acid with antibiotics can significantly improve the bactericidal effect of the antibiotics, which has better effects and higher safety and operability compared with only using antibiotics as antibacterial drugs at present.

Abstract: Formulations, methods of manufacturing, methods of stabilizing, kits, and uses as medicament are provided, for example for the treatment of pain. The formulations can comprise gabapentin optionally combined with at least one non-opioid pain drug in an aqueous carrier. The pharmaceutical formulation can have a pH of about 2.0 to about 10.0. The at least one non-opioid pain drug can be acetaminophen. The components can be included in any amount suitable for purposes of obtaining properties desirable for an injectable infusion, for example an intravenous infusion.

Abstract: The invention provides compositions and methods of treating autism. Specifically, the invention relates to treating the core symptoms of autism by administering ?-methyl-DL-tyrosine.

Abstract: The present disclosure describes methods of administering N-acetylcysteine (NAC) via intranasal administration. The effect of intranasal NAC administration can be monitored using an analytical technique, for example, magnetic resonance spectroscopy (MRS). In some embodiments, intranasal NAC can be used to treat a condition. In some embodiments, MRS can be used to monitor the effect of intranasal NAC administration or to modify the dosage of intranasal NAC administration to treat a condition.

Abstract: A self-emulsifying composition which comprises, when taking the total amount of the self-emulsifying composition as 100 mass %, 70 to 90 mass % of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids, pharmaceutically acceptable salts thereof, and esters of the same, 0.5 to 6 mass % of water and 1 to 29 mass % of an emulsifying agent that comprises a polyoxyethylene sorbitan fatty acid ester (and that further contains a polyoxyl castor oil optionally, with the proviso that the emulsifying agent does not include lecithin) and which contains 3 to 40 parts by mass of lecithin relative to 100 parts by weight of the ?3 polyunsaturated fatty acid or the like. This self-emulsifying composition exhibits excellent self-emulsifying properties, composition dispersibility, emulsion stability and absorbability, and does not contain ethanol or a polyhydric alcohol or contains the same only in a low concentration. The self-emulsifying composition is useful for food and medicine.

Abstract: Pharmaceutical compositions include a prodrug of epinephrine are described.

Abstract: Method of treating Philadelphia-negative myeloproliferative syndromes in a patient suffering therefrom by administering to the patient diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride, or other pharmaceutically acceptable salts and/or solvates, in a daily dosage amount of from 50 to 100 mg per patient.

Abstract: This invention relates to the treatment of breast cancer in a subject, for example a female subject.

Abstract: In the broadest aspect, the invention provides a composition for and a method of prophylactic and/or therapeutic treatment of a animal/mammal for any viral disease, mixed bacterial and viral infections, bacterial infections, bacterial endotoxins, bacterial exotoxins, autoimmune diseases, and cellular or humoral mediated allergic conditions that is caused by any virus that relies on the maintenance of specific calcium ion concentrations for the post ribosomal RNA synthesis processing of viral protein translation, transportation and processing of viral structural components by utilizing a therapeutic amount of a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof, of calmodulin blocker and a metabolite thereof, and a pharmaceutical acceptable diluent or carrier, and/or is caused by damage to the animal/mammal by a pathological immune response to antigens.

Abstract: The present invention relates to a remedy against androgenetic alopecia, consisting of a combination or formulation comprising zinc and arginine gluconates combined with ascorbic acid.

Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.

Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Abstract: The present invention provides cannabinoid-containing topical compositions that are useful in treating and/or preventing at least one disease selected from the group consisting of atopic dermatitis, eczema, dry skin, baby rash, psoriasis, neuropathic pruritis, acne vulgaris, shingles, hives, sunburn, rosacea and flaky skin in a subject in need thereof.

Abstract: A method for producing a fatty acid-cannabinoid-plasma protein (FCP) composition, the method comprising: contacting a plasma protein or a peptide portion thereof with a supplemental fatty acid composition comprising at least one fatty acid; and contacting the plasma protein or portion thereof with a cannabinoid composition comprising at least one cannabinoid, such that a combined composition is prepared, which comprises a FCP complex in which the at least one fatty acid and the at least one cannabinoid is bound to the plasma protein or portion thereof.

Abstract: A composition includes two or more isoflavone compounds and a pharmaceutically acceptable carrier. In some cases, the isoflavone compounds can include calycosin, formononetin, or daidzein. The composition can be used in methods to treat a subject having at risk of having cerebral ischemia-reperfusion injury and/or hypoxia brain injury.

Abstract: Provided are compositions comprising a cannabinoid, an oil (e.g., MCT oil or coconut oil), and a wax, and methods of making such compositions. The disclosed compositions can be useful in, for example, treating an injury of the muscle, joint, cartilage, and/or tendon. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Provided is a method for treating conditions and/or symptoms associated therewith selected from the group consisting of androgen deficiency, male infertility, male urogenital or reproductive system infections and/or disorders and combinations thereof, comprising administering to a subject in need a therapeutically effective amount of a composition comprising at least one cannabinoid in a specific amount, at least one terpene in a specific amount, at least 5% by weight of a non-cannabinoid, non-terpene carrier, and optionally at least one herbal extract, wherein said non-cannabinoid, non-terpene carrier comprises cellulose and a weight/weight ratio of a total amount of terpenes to a total amount of cannabinoids is from about 0.1:1 to about 1:1, or; wherein said non-cannabinoid, non-terpene carrier comprises less than 5% by weight cellulose and a weight/weight ratio of a total amount of terpenes to a total amount cannabinoids is about 0.05:1 to about 1:1.

Abstract: The present invention relates to medicaments for use in the prophylaxis or treatment of vasoconstriction related disorders or conditions. Specifically, the present invention relates to (2R) enantiomeric form of a 6-chromanol derivative for use in the prophylactic or treatment of vasoconstriction related disorders or conditions. A preferred 6-chromanol derivative is (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone; N-(benzyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide; N-(phenyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide; methyl 4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamido)benzoate; (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(morpholino)methanone, and pharmaceutically acceptable salts thereof.

Abstract: The present invention relates to a composition for use in the treatment of an intestinal tract disorder caused by a gluten-associated protein, said composition comprising at least one agent which binds to the gluten-associated protein, characterized in that the composition is administered at the same time as or at most within 60 minutes after administration of at least one tannin to a patient.

Abstract: The present invention provides therapeutic compound for prevention and treatment of primary biliary cholangitis, (PBC). Specifically, the present invention provides pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of PBC.

Abstract: Provided herein are compositions suitable for treating chemically induced eye damage comprising (a) a nonsteroidal anti-inflammatory drug (NSAID), (b) a histone deacetylase (HDAC) inhibitor and (c) an angiotensin converting enzyme (ACE) inhibitor and, optionally, (d) a water-soluble vitamin. Methods of using provided compositions to treat ocular toxicity and corneal damage following exposure to chemical agents (e.g., mustard gas) are also provided.

Abstract: A pharmaceutical composition includes a ferrochelatase inhibitor and a pharmaceutically acceptable carrier. In another aspect, a method of treating a subject having, or a t risk of having, a hemorrhagic stroke generally includes administering to the subject a pharmaceutical composition that includes a ferrochelatase inhibitor in an amount effective to ameliorate at least one symptom or clinical sign of hemorrhagic stroke.

Abstract: Disclosed herein are methods of using a 5-HT2A serotonin receptor inverse agonist for the prophylaxis and/or treatment of psychosis or psychotic symptoms in an individual comprising administering to said individual in need thereof a therapeutically effective amount of said 5-HT2A serotonin receptor inverse agonist.

Abstract: An object of the present invention is to provide a highly stable medicament comprising a pyrazolone derivative such as edaravone, which is free of sodium bisulfite. The present invention provides a medicament, comprising (a) a pyrazolone derivative such as 3-methyl-1-phenyl-2-pyrazolin-5-one; (b) a glutathione analogue, and (c) an aqueous solvent, which comprises none of sulfite, bisulfite, and pyrosulfite, and is subjected to deoxygenation treatment.

Abstract: The present application relates to novel 3-imidazolines of formula (I?) and (I) below: (I?) (I) Wherein Ar1, Ar2, Ar3, and R1 to R6 are as defined in the claims. The 3-imidazolines of the invention are useful in antibiotic therapies, in particular as inhibitors of carbapenemases. They are also useful as antibiotics themselves. The present invention also concerns a method for preparing more specifically the 3-imidazolines of formula (I). The present invention further relates to conjugates of said compounds with known antibiotics.

Abstract: The present disclosure relates to a field of compounds, and more particularly, a stable composition including angiotensin II, a preparation method, and an application method thereof. The composition may include: the angiotensin II; and an excipient, including one or more substances selected from a sugar, an alcohol, a polymer, a surfactant, or an amino acid. The present disclosure may be used for the stable composition including the angiotensin II with high stability, and may be stored under room temperature for more than two years, which solves a problem that the poor stability of the angiotensin II requires cold chain transportation and storage, thereby greatly improving the security and effectiveness of the medicine.

Abstract: The present disclosure relates generally to modulators of human glycolate oxidase enzyme and methods of use and manufacture thereof.

Abstract: This invention relates to topical compositions for combating ectoparasites and endoparasites in animals, comprising at least one isoxazoline active agent and a pharmaceutically acceptable carrier, optionally in combination with one or more additional active agents. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof.

Abstract: A novel platform for manufacturing storage stable and effective drug delivery systems.

Abstract: The disclosure relates to substituted fused heteroaromatic tricyclic compounds and the use thereof. Specifically, the disclosure provides compounds of the following Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein A1-A3, B1-B3, D1-D4 and R1-R2 are defined herein. Compounds having Formula I are ATM kinase inhibitors. Therefore, compounds of the disclosure may be used to treat clinical conditions caused by DDR functional defects, such as cancer.

Abstract: The present disclosure relates to pharmaceutical formulations including a weakly basic drug and an ionic polymer in an amorphous solid dispersion, as well as methods of forming such pharmaceutical formulations, and methods of administering such pharmaceutical formulations.

Abstract: Described herein are compounds useful for preventing and/or treating a disease or condition relating to aberrant function of a T-type calcium channel, such as epilepsy and epilepsy syndromes (e.g., absence seizures, juvenile myoclonic epilepsy, or a genetic epilepsy) and mood disorders. The present invention further comprises methods for modulating the function of a T-type calcium channel.

Abstract: Provided are methods for treating cancer in a patient by administering at least one antibiotic selected from the group consisting of clofazimine, rifabutin and clarithromycin, in combination with an aryladamantane compound. In an embodiment, the aryladamantane compound is [3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide], or a pharmaceutically acceptable salt thereof.

Abstract: Sustained release pharmaceutical compositions comprising a therapeutically effective amount of pyridostigmine or a pharmaceutically acceptable salt thereof, a diluent, and a copolymer comprising polyvinyl acetate and polyvinylpyrrolidone, wherein the compositions are produced by hot-melt extrusion.